

**EUROPEAN
CURRICULUM VITAE
FORMAT**



PERSONAL INFORMATION

Name **GIUSEPPE LO RUSSO**

Nationality Italian
Date of birth 30 OCTOBER 1982
City of birth

WORK EXPERIENCE

- Dates (from – to) **APRIL 2018- SEPTEMBER 2018**
- Name and address of employer The Ohio State University Comprehensive Cancer Center,
College of Medicine, Department of Cancer Biology and Genetics (CBG),
Columbus, Ohio, USA
Comprehensive Cancer Center
- Type of business or sector Exchange Visitor
- Occupation or position held Biomedical Research,
- Main activities and responsibilities Pre-clinical Cancer Research with peculiar interest for Thoracic Tumors

- Dates (from – to) **DECEMBER 2014 - PRESENT**
- Name and address of employer Fondazione IRCCS – Istituto Nazionale Tumori
Via G. Venezian, 1 - 20133 Milano, Italy
Public Hospital
- Type of business or sector Oncologist - Resident
- Occupation or position held Clinical management of cancer patients with peculiar interest for Thoracic tumors,
Neuroendocrine tumors, Translational research and Clinical trials
- Main activities and responsibilities

- Dates (from – to) **SEPTEMBER 2012 – JULY 2014**
- Name and address of employer ICOT hospital
Latina, Italy
Public Hospital
- Type of business or sector Postgraduate medical training
- Occupation or position held Clinical management of cancer patients, Translational research and Clinical trials
- Main activities and responsibilities

- Dates (from – to) **JULY 2009 – JULY 2014**
- Name and address of employer Distretto 1 ASL Latina
Aprilia, Italy
Public Hospital
- Type of business or sector

- Occupation or position held
- Main activities and responsibilities

Postgraduate medical training
Clinical management of cancer patients, Translational research and Clinical trials

- Dates (from – to)
- Name and address of employer

JULY 2009 – SEPTEMBER 2012

Santa Maria Goretti Hospital
Latina, Italy
Public Hospital
Postgraduate medical training
Clinical management of cancer patients, Translational research and Clinical trials

- Type of business or sector
- Occupation or position held
- Main activities and responsibilities

EDUCATION AND TRAINING

- Dates (from – to)
- Name and type of organisation providing education and training
- Principal subjects/occupational skills covered
- Title of qualification awarded

DECEMBER 2014 – FEBRUARY 2018

“Sapienza” University of Rome

Translational research

Ph. D. in Medical Oncology

- Dates (from – to)
- Name and type of organisation providing education and training
- Principal subjects/occupational skills covered
- Title of qualification awarded

JULY 2009 – JULY 2014

“Sapienza” University of Rome

Clinical Oncology

Specialization in Medical Oncology graduated with honor

- Dates (from – to)
- Name and type of organisation providing education and training
- Principal subjects/occupational skills covered
- Title of qualification awarded

SEPTEMBER 2001- MARCH 2008

“Sapienza” University of Rome

Medicine

Degree in Medicine (MD – Medical Doctor) with honor

**PERSONAL SKILLS
AND COMPETENCES**

MOTHER TONGUE
OTHER LANGUAGES

ITALIAN

ENGLISH

EXCELLENT
EXCELLENT
EXCELLENT

- Reading skills
- Writing skills
- Verbal skills

**ORGANISATIONAL SKILLS
AND COMPETENCES**

CLINICAL MANAGEMENT OF CANCER PATIENTS

PREPARATION OF RESEARCH PROJECTS

MANAGEMENT OF CLINICAL TRIALS (PHASE I, II AND III) AS SUB-INVESTIGATOR

(EXPERIENCE AS PRINCIPAL-INVESTIGATOR IN ABOUT 60 CLINICAL TRIALS FOCUSING

ON THORACIC TUMORS)

TECHNICAL SKILLS AND COMPETENCES	OFFICE PACKAGE, RESEARCH IN PUBLIC DATABASE
RELATIONSHIP SKILLS	GOOD ATTITUDE AND CAPACITY TO WORK IN GROUP GOOD CAPACITY OF COMMUNICATION
PRIZES AND AWARDS	15.04.2008 PREMIO FORTUNATO PERUGINI 27.09.2019 ESMO LEADERS GRADUATED
GRANT	MFAG 2019 AIRC
SCIENTIFIC AFFILIATIONS	ITALIAN ASSOCIATION OF MEDICAL ONCOLOGY – AIOM EUROPEAN SOCIETY OF MEDICAL ONCOLOGY – ESMO GCP TRAINING: 26.04.2022

International journals:

1. Ozel A, Kirdar A, Halefoglu AM, Erturk SM, Karpat Z, **Lo Russo G**, Maldur V, Cantisani V. Cysts of the canal of Nuck: ultrasound and magnetic resonance imaging findings. *J Ultrasound* 2009; 12(3):125-7.
2. **Lo Russo G**, Franchi F, Seminara P. Is CEA Better than CYFRA 21-1 in the Monitoring of Squamous Cell Lung Cancer Progression? *Medical Principles and Practice*. 2011; 20(2):200.
3. Papa A, Rossi L, **Lo Russo G**, Giordani E, Spinelli GP, Zullo A, Petrozza V, Tomao S. Emerging Role of Cetuximab in the Treatment of Colorectal Cancer. *Recent Patents on Anti-Cancer Drug Discovery*. 2012; 7(2):233-47
4. Spinelli GP, Miele E, **Lo Russo G**, Miscusi M, Codacci-Pisanelli G, Petrozza V, Papa A, Frati L, Della Rocca C, Gulino A, Tomao S. Chemotherapy and target therapy in the management of adult high-grade gliomas. *Curr Cancer Drug Targets*. 2012;12(8):1016-31.
5. Spinelli GP, **Lo Russo G**, Miele E, Prinzi N, Tomao F, Antonelli M, Giangaspero F, Stati V, Strudel M, Tomao S. Breast cancer metastatic to the pituitary gland: a case report. *World J Surg Oncol*. 2012;10:137
6. **Lo Russo G**, Accarpio F, Spinelli GP, Miele E, Borriani F, Cerbone L, Stati V, Prinzi N, Strudel M, Sibio S, Tomao S. Subcutaneous metastases from colon cancer: a case report. *J Med Case Rep*. 2012;6(1):212.
7. **Lo Russo G**, Spinelli GP, Tomao S, Rossi B, Frati L, Panici PB, Vici P, Codacci Pisanelli G, Tomao F. Breast cancer risk after exposure to fertility drugs. *Expert Rev Anticancer Ther*. 2013;13(2):149-57.
8. Spinelli GP, **Lo Russo G**, Pacchiarotti A, Stati V, Prete AA, Tomao F, Sciarretta C, Arduin M, Basso E, Chiotti S, Sinjari M, Venezia M, Zoccoli G, Tomao S. A 68-year-old Caucasian man presenting with urinary bladder lymphoepithelioma: a case report. *J Med Case Rep*. 2013 ;7(1):161.
9. Gazzaniga P, Gianni W, Raimondi C, Gradilone A, **Lo Russo G**, Longo F, Gandini O, Tomao S, Frati L. Circulating tumor cells in high-risk nonmetastatic colorectal cancer. *Tumour Biol*. 2013;34(5):2507-9.
10. Gazzaniga P, Raimondi C, Gradilone A, Biondi Zoccai G, Nicolazzo C, Gandini O, Longo F, Tomao S, **Lo Russo G**, Seminara P, Vincenzi B, Chimenti I, Cristofanilli M, Frati L, Cortesi E. Circulating tumor cells in metastatic colorectal cancer: do we need an alternative cutoff? *J Cancer Res Clin Oncol*. 2013;139(8):1411-6.
11. Tomao F, Papa A, Rossi L, Strudel M, Vici P, **Lo Russo G**, Tomao S. Emerging role of cancer stem cells in the biology and treatment of ovarian cancer: basic knowledge and therapeutic possibilities for an innovative approach. *J Exp Clin Cancer Res*. 2013;32:48.
12. Rossi L, Tomao F, **Lo Russo G**, Papa A, Zoratto F, Marzano R, Basso E, Giordani E, Verrico M, Ricci F, Pasciuti G, Francini E, Tomao S. Efficacy and safety analysis of once per cycle pegfilgrastim and daily lenograstim in patients with breast cancer receiving adjuvant myelosuppressive chemotherapy FEC 100: a pilot study. *Ther Clin Risk Manag*. 2013;9:457-62.
13. Rossi L, Vakiarou F, Zoratto F, Bianchi L, Papa A, Basso E, Verrico M, **Lo Russo G**, Evangelista S, Rinaldi G, Perrone-Congedi F, Spinelli GP, Stati V, Caruso D, Prete A, Tomao S. Factors influencing choice of chemotherapy in metastatic colorectal cancer (mCRC). *Cancer Manag Res*. 2013;5:377-385
14. Tomao F, Papa A, Strudel M, Rossi L, **Lo Russo G**, Benedetti Panici P, Ciabatta FR, Tomao S. Investigating Molecular Profiles of Ovarian Cancer: An Update on Cancer Stem Cells. *J. Cancer* 2014; 5(5): 301-310.
15. Tomao F, **Lo Russo G**, Spinelli GP, Tomao F. Clinical use of fertility agents and risk of breast cancer: a recent update for an old problem. *Curr Opin Obstet Gynecol* 2014, 26(3):130-137. (First name, equal contribute to the first author).
16. *Spinelli GP, Stati V, Prete AA, **Lo Russo G**, Miele E, Sinjari M, Chiotti MS, Ciabatta FR, Rossi B, Tomao S. Bevacizumab in glioblastomas: lights and shadows. *Reviews in Oncology* 2013; 1 (4): 123-133.
17. Tomao F, **Lo Russo G**, Spinelli GP, Stati V, Prete AA, Prinzi N, Sinjari M, Vici P, Papa A, Chiotti MS, Benedetti Panici P, Tomao S. Fertility drugs, reproductive strategies and ovarian cancer risk. *J Ovarian Res*. 2014;7:51. eCollection 2014. (First name, equal contribute to the first author).
18. Zoratto F, Rossi L, Verrico M, Papa A, Basso E, Zullo A, Tomao L, Romiti A, **Lo Russo G**, Tomao S. Focus on genetic and epigenetic events of colorectal cancer pathogenesis: implications for molecular diagnosis. *Tumour Biol*. 2014;35(7):6195-6206.

19. Tomao F, Papa A, **Lo Russo G**, Zuber S, Spinelli GP, Rossi L, Caruso D, Prinzi N, Stati V, Benedetti Panici P, Tomao S. Correlation between fertility drugs use and malignant melanoma incidence: the state of the art. *Tumour Biol* 2014; 35:8415-8424. (First name, equal contribute to the first author).
20. **Lo Russo G**, Tomao F, Spinelli GP, Prete AA, Stati V, Benedetti Panici P, Papa A, Tomao S. Fertility drugs and breast cancer risk. *Eur J Gynaecol Oncol* 2015;36(2):107-13.
21. *Spinelli GP, Miele E, **Lo Russo G**, Rossi B, Tomao S. *Acrocyanosis, Digital Ischemia and Acronecrosis as First Manifestations of Endometrial Adenocarcinoma: Case Presentation and Literature Review. Int J Gynecol Clin Pract* 2016, 2: 113.
22. Signorelli D, Macerelli M, Proto C, Vitali M, Cona MS, Agustoni F, Zilembo N, Platania M, Trama A, Gallucci R, Ganzinelli M, Pelosi G, Pastorino U, de Braud F, Garassino MC, **Lo Russo G**. Systemic approach to malignant pleural mesothelioma: what news of chemotherapy, targeted agents and immunotherapy? *Tumori* 2016;102(1):18-30.
23. **Lo Russo G**, Proto C, Garassino MC. Afatinib in the treatment of squamous Non-Small Cell Lung Cancer: a new frontier or an old mistake? *TLCR* 2016 ;5(1):110-4.
24. Pusceddu S, **Lo Russo G**, Macerelli M, Proto C, Vitali M, Signorelli D, Ganzinelli M, Scanagatta P, Duranti L, Trama A, Buzzoni R, Pelosi G, Pastorino U, de Braud F, Garassino MC. Diagnosis and management of typical and atypical lung carcinoids. *Crit Rev Oncol Hematol* 2016; 100:167-76 (First name, equal contribute to the first author).
25. **Lo Russo G**, Pusceddu S, Proto C, Lo Russo G, Signorelli D, Vitali M, Ganzinelli M, Gallucci R, Zilembo N, Platania M, Buzzoni R, de Braud F, Marina Garassino MC. Treatment of lung large cell neuroendocrine carcinoma. *Tumour Biol* 2016; 37(6):7047-57.
26. **Lo Russo G**, Imbimbo M, Garassino MC. Is the chemotherapy era in advanced non-small cell lung cancer really over? Maybe not yet. *Tumori* 2016; (3):223-5.
27. Pusceddu S, De Braud F, **Lo Russo G**, Concas L, Femia D, Vernieri C, Indini A, Formisano B, Buzzoni R. How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies. *Oncotarget*. 2016; 7(28):44841-44847
28. **Lo Russo G**, Macerelli M, Platania M, Zilembo N, Vitali M, Signorelli D, Proto C, Ganzinelli M, Gallucci R, Agustoni F, Fasola G, de Braud F, Garassino MC. SMALL-CELL LUNG CANCER: CLINICAL MANAGEMENT AND UNMET NEEDS. New perspectives for an old problem. *Curr Drug Targets*. 2016; 18(3):341-362.
29. Pusceddu S, Femia D, **Lo Russo G**, Ortolani S, Milione M, Maccauro M, Vernieri C, Prinzi N, Concas L, Leuzzi L, De Braud F, Buzzoni R. Update on medical treatment of small intestinal neuroendocrine tumors. *Expert Rev Anticancer Ther* 2016 ; 13:1-8
30. **Lo Russo G**, Pusceddu S, Prinzi N, Imbimbo M, Proto C, Signorelli D, Vitali M, Ganzinelli M, Maccauro M, Buzzoni R, Seregini E, de Braud F, Garassino MC. Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors. *Tumour Biol*. 2016; 37(10):12991-13003.
31. Imbimbo M, **Lo Russo G**, Blackhall F. Current status of immunotherapy for non-small-cell lung cancer. *Tumori* 2016; 102(4):337-51.
32. Califano R, Kerr K, Morgan RD, **Lo Russo G**, Garassino M, Morgillo F, Rossi A. Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer. *Curr Oncol Rep*. 2016;18(9):59
33. Vernieri C, Femia D, Pusceddu S, Capella C, Rosai J, Calareso G, Concas L, Prinzi N, **Lo Russo G**, de Braud F, Buzzoni R. Primary Cerebellar Neuroendocrine Tumors: Chimeras or Real Entities? A Case Report with a 6-Year Follow-Up. *Case Rep Oncol* 2016, 9(2): 432-439.
34. Proto C, Imbimbo M, Gallucci R, Brissa A, Signorelli D, Vitali M, Macerelli M, Corrao G, Ganzinelli M, Greco FG, Garassino MC, **Lo Russo G**. Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future. *TLCR* 2016;5(6):563-578
35. Pusceddu S, Verzoni E, Prinzi N, Mennitto A, Femia D, Grassi P, Concas L, Vernieri C, **Lo Russo G**, Procopio G. Everolimus treatment for neuroendocrine tumors: latest results and clinical potential. *Ther Adv Med Oncol*. 2017; 9(3):183-188.
36. Marchianò AV, Cosentino M, Di Tolla G, Greco FG, Silva M, Sverzellati N, Fabbri A, Tamborini E, **Lo Russo G**, Mariani L, Lalli L, Pastorino U. FNA and CNB in the diagnosis of pulmonary lesions: a single-center experience on 665 patients, comparison between two periods. *Tumori*. 2017; 103(4):360-366.
37. **Lo Russo G**, Imbimbo M, Corrao G, Proto C, Signorelli D, Vitali M, Ganzinelli M, Botta L, Zilembo N, de Braud F, Garassino MC. Concomitant EML4-ALK rearrangement and EGFR mutation in non small cell lung cancer patients: A literature review of 100 cases. *Oncotarget*. 2017; 8(35): 59889-59900.

38. Pusceddu S, Prinzi N, **Lo Russo G**, Femia D, Milione M, Perrone F, Tamborini E, Concas L, Pulice I, Vernieri C, Corti F, Buzzoni R, de Braud F. Rationale and protocol of MetNET-2 trial: Lanreotide Autogel plus metformin in advanced gastrointestinal or lung neuroendocrine tumors. *Future Oncol.* 2017; 13(19):1677-1683.
39. Proto C, **Lo Russo G**, Corrao C, Ganzinelli M, Facchinetti F, Minari R, Tiseo M, Garassino MC. Treatment in EGFR-mutated non-small cell lung cancer: how to block the receptor and overcome resistance mechanisms. *Tumori* 2017; 103(4):325-337
40. Vitali M, Ripamonti CI, Roila F, Proto C, Signorelli D, Imbimbo M, Corrao G, Brissa A, Rosaria G, de Braud F, Garassino MC, **Lo Russo G**. Cognitive impairment and chemotherapy: a brief overview. *Crit Rev Oncol Hematol.* 2017; 118:7-14.
41. Metro G, Passaro A, **Lo Russo G**, Bonanno L, Giusti R, Gregorc V, Capelletto E, Martelli O, Cecere FL, Giannarelli D, Luciani A, Bearz A, Tuzi A, Scotti V, Tonini G, Galetta D, Carta A, Soto Parra H, Rebonato A, Morabito A, Chiari R. Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. *Future Oncol.* 2018; 14(4): 353–361.
42. Galli G, Corrao G, Imbimbo M, Proto C, Signorelli D, Ganzinelli M, Zilembo N, Vitali M, de Braud F, Garassino MC, **Lo Russo G**. Uncommon mutations in epidermal growth factor receptor and response to first and second generation tyrosine kinase inhibitors: A case series and literature review. *Lung Cancer.* 2018;115:135-142.
43. Inno A, **Lo Russo G**, Salgarello M, Corrao G, Casolino R, Galli G, Modena A, Romano L, Pusceddu S, Greco FG, Garassino MC, Gori S. The evolving landscape of criteria for evaluating tumor response in the era of cancer immunotherapy: From Karnofsky to iRECIST. *Tumori* 2018;104(2):88-95. (First name, equal contribute to the first author).
44. Pusceddu S, Vernieri C, Di Maio M, Marconcini R, Spada F, Massironi S, Ibrahim T, Brizzi MP, Campana D, Faggiano A, Giuffrida D, Rinzivillo M, Cingarlini S, Aroldi F, Antonuzzo L, Berardi R, Catena L, De Divitiis C, Ermacora P, Perfetti V, Fontana A, Razzore P, Carnaghi C, Davi MV, Cauchi C, Duro M, Ricci S, Fazio N, Cavalcoli F, Bongiovanni A, La Salvia A, Brighi N, Colao A, Puliafito I, Panzuto F, Ortolani S, Zaniboni A, Di Costanzo F, Torniai M, Bajetta E, Tafuto S, Garattini SK, Femia D, Prinzi N, Concas L, **Lo Russo G**, Milione M, Giacomelli L, Buzzoni R, Delle Fave G, Mazzaferro V, de Braud F. Metformin Use Associates With Longer Progression-free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. *Gastroenterology.* 2018;155(2):479-489.
45. Garassino MC, Gelibter AJ, Grossi F, Chiari R, Soto Parra H, Cascinu S, Cognetti F, Turci D, Blasi L, Bengala C, Mini E, Baldini EE, Quadri S, Ceresoli GL, Antonelli P, Vasile E, Pinto C, Fasola G, Galetta D, Macerelli M, Giannarelli D, **Lo Russo G**, de Marinis F. Italian nivolumab expanded access program in nonsquamous non-small-cell lung cancer patients: results in never-smokers and EGFR-mutant patients. A multicentric experience. *Journal of Thoracic Oncology.* 2018; 13(8): 1146-1155. (Corresponding Author).
46. Pusceddu S, Barretta F, Trama A, Botta L, Milione M, Buzzoni R, De Braud F, Mazzaferro V, Pastorino U, Seregni E, Mariani L, Gatta G, Di Bartolomeo M, Femia D, Prinzi N, Coppa J, Panzuto F, Antonuzzo L, Bajetta E, Brizzi MP, Campana D, Catena L, Comber H, Dwane F, Fazio N, Faggiano A, Giuffrida D, Henau K, Ibrahim T, Marconcini R, Massironi S, Žakelj MP, Spada F, Tafuto S, Van Eycken E, Van der Zwan JM, Žagar T, Giacomelli L, Miceli R; **NEPscore Working Group**. A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors. *Endocr Relat Cancer.* 2018;25(6):607-618. (NEPscore Working Group).
47. Fucà G, Galli G, Poggi M, **Lo Russo G**, Proto C, Imbimbo M, Vitali M, Ganzinelli M, Lanti C, Molino G, Stangoni F, Zilembo N, de Braud F, Garassino MC, Signorelli D. Low Baseline Serum Sodium Concentration Is Associated with Poor Clinical Outcomes in Metastatic Non-Small Cell Lung Cancer Patients Treated with Immunotherapy. *Target Oncol.* 2018;13(6):795-800.
48. **Lo Russo G**, Moro M, Sommariva M, Cancila V, Boeri M, Centonze G, Ferro S, Ganzinelli M, Gasparini P, Huber V, Milione M, Porcu L, Proto C, Pruneri G, Signorelli D, Sangaletti S, Sfondrini L, Storti C, Tassi E, Bardelli A, Marsoni S, Torri V, Tripodo C, Colombo MP, Anichini A, Rivoltini L, Balsari A, Sozzi G, Garassino M. Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-Small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade. *Clin Cancer Res.* 2019;25(3):989-999.
49. Imbimbo M, Ottaviano M, Vitali M, Fabbri A, Leuzzi G, Fiore M, Franceschini D, Pasello G, Perrino M, Schiavon M, Pruneri G, Dei Tos AP, Sangalli C, Garassino MC, Berardi R, Alessi A, Calareso G, Petrini I, Scorsetti M, Scotti V, Rosso L, Rea F, Pastorino U, Casali PG, Ramella S, Ricardi U, Abate-Daga L, Torri V, Trama A, Palmieri G, Marino M, Zucali PA; **TYME network collaborators**. Best practices for the management of thymic

- epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME). *Cancer Treat Rev*. 2018 71:76-87. (TYME network collaborators).
50. Garassino MC, Crinò L, Catino A, Ardizzoni A, Cortesi E, Cappuzzo F, Bordi P, Calabrò L, Barbieri F, Santo A, Altavilla G, Ambrosio F, Mini E, Vasile E, Morgillo F, Scoppola A, Bengala C, Follador A, Tedde N, Giannarelli D, **Lo Russo G**, Vitiello F. Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: Results from the Italian cohort of an expanded access program. *Tumour Biol*. 2018;40(11):1010428318815047. (Corresponding Author).
 51. **Lo Russo G**, Tessari A, Capece M, Galli G, de Braud F, Garassino MC, Palmieri D. MicroRNAs for the Diagnosis and Management of Malignant Pleural Mesothelioma: A Literature Review. *Front Oncol* 2018;8:650.
 52. Horn L, Mansfield AS, Szczesna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, Reck M, Mok T, Lam S, Shames DS, Liu J, Ding B, Lopez-Chavez A, Kabbinar F, Lin W, Sandler A, Liu SV; IMpower133 Study Group. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. *N Engl J Med*. 2018 Dec 6;379(23):2220-2229. (Collaborators).
 53. Boeri M, Milione M, Proto C, Signorelli D, **Lo Russo G**, Galeone C, Verri C, Mensah M, Centonze G, Martinetti A, Sottotetti E, Pastorino U, Garassino MC, Sozzi G. Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study. *Clin Cancer Res* 2019 doi: 10.1158/1078-0432.CCR-18-1981.
 54. Fucà G, Galli G, Poggi M, **Lo Russo G**, Proto C, Imbimbo M, Ferrara R, Zilembo N, Ganzinelli M, Sica A, Torri V, Colombo MP, Vernieri C, Balsari A, de Braud F, Garassino MC, Signorelli D. Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. *ESMO Open* 2019;4:e000457.
 55. Spinelli GP, Miele E, Prete AA, **Lo Russo G**, Di Marzo A, Di Cristofano C, Tomao S. Combined surgery and radiotherapy as curative treatment for tracheal adenoid cystic carcinoma: a case report. *J Med Case Rep*. 2019 6;13(1):52.
 56. Platania M, Pasinib F, Porcu L, Boeri M, Verderame F, Modena Y, Del Conte A, Nichetti F, Garassino MC, Martinetti A, Sottotetti E, Cavanna L, Vattemi E, Pozzessere D, Bertolini A, Irtelli L, Verri C, Sozzi G, Protoa C, Pastorino U, Torri V, Fraccon AP, Spinnato F, Signorelli D, **Lo Russo G**, Tuzio A, Gallucci R, Cinieri S, Mencoboni M, Antonelli P, Giacomelli L, de Braud F. Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trial. *Lung Cancer* 2019; 132: 17–23
 57. Proto C, Ferrara R, Signorelli D, **Lo Russo G**, Galli G, Imbimbo M, Prelaj A, Zilembo N, Ganzinelli M, Pallavicini LM, De Simone I, Colombo MP, Sica A, Torri V, Garassino MC. Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): What to add and what to leave out. *Cancer Treat Rev* 2019; 75:39–51
 58. Galli G, Triulzi T, Proto C, Signorelli D, Imbimbo M, Poggi M, Fucà M, Ganzinelli M, Vitali M, Palmieri D, Tessari A, de Braud F, Garassino MC, Colombo MP, **Lo Russo G**. Association between antibiotic-immunotherapy exposure ratio and outcome in metastatic non small cell lung cancer. *Lung cancer* 2019;132:72-78.
 59. Crinò L, Bidoli P, Delmonte A, Grossi F, De Marinis F, Ardizzoni A, Vitiello F, **Lo Russo G**, Parra HS, Cortesi E, Cappuzzo F, Calabrò L, Tiseo M, Turci D, Gamucci T, Antonelli P, Morabito A, Chella A, Giannarelli D, Galetta D. Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population. *Oncologist* 2019; 24(11):e1165-e1171
 60. Galli G, Proto C, Signorelli D, Imbimbo M, Ferrara R, Prelaj A, De Toma A, Ganzinelli M, Zilembo N, de Braud F, Garassino MC, **Lo Russo G**. Characterization of patients with metastatic non-small-cell lung cancer obtaining long-term benefit from immunotherapy. *Future Oncol* 2019; 15(23):2743-2757.
 61. Proto C, Signorelli D, Mallone S, Prelaj A, **Lo Russo G**, Imbimbo M, Galli G, Ferrara R, Ganzinelli M, Leuzzi G, Greco FG, Calareso G, Botta L, Gatta G, Garassino M, Trama A. The Prognostic Role of TNM Staging Compared With Tumor Volume and Number of Pleural Sites in Malignant Pleural Mesothelioma. *Clin Lung Cancer* 2019;20(6):e652-e660.
 62. Prinzi N, Raimondi A, Maccauro M, Milione M, Garanzini E, Torchio M, Corti F, Nichetti F, **Lo Russo G**, Giacomelli L, Mazzaferro V, Di Bartolomeo M, Seregini E, de Braud F, Pusceddu S. Somatostatin analogs in association with peptide receptor radionuclide therapy in advanced well-differentiated NETs. *Future Oncol* 2019;15(26):3015-3024.
 63. Galli G, Proto C, Cossa M, Valeri B, Sdao S, Signorelli D, Imbimbo M, de Braud F,

- Garassino MC, **Lo Russo G**. Unusual skin toxicity associated with sustained disease response induced by nivolumab in a patient with non-small cell lung cancer. *Tumori* 2019; 105(6):NP57-NP62.
64. Galli G, De Toma A, Pagani F, Randon G, Trevisan B, Prelaj A, Ferrara R, Proto C, Signorelli D, Ganzinelli M, Zilembo N, de Braud F, Garassino MC, **Lo Russo G**. Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer. *Lung Cancer* 2019;137:38-42
 65. Berardi R, Mastroianni C, **Lo Russo G**, Buosi R, Santini D, Montanino A, Carnaghi C, Tiseo M, Chiari R, Camerini A, Barni S, De Marino VI, Ferrari D, Cristofano A, Doni L, Freddari F, Fumagalli D, Portalone L, Sarmiento R, Schinzari G, Sperandi F, Tucci M, Inno A, Ciuffreda L, Mariotti M, Mariani C, Caramanti M. Syndrome of inappropriate anti-diuretic hormone secretion in cancer patients: results of the first multicenter Italian study. *Ther Adv Med Oncol* 2019; 11:1-13.
 66. Prelaj A, Ferrara R, Rebuzzi SE, Proto C, Signorelli D, Galli G, De Toma A, Randon G, Pagani F, Viscardi G, Brambilla M, Trevisan B, Ganzinelli M, Martinetti A, Gallucci R, Di Mauro RM, Molino G, Zilembo N, Torri V, de Braud FM, Garassino MC, **Lo Russo G**. EPSiLoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort. *Cancers (Basel)*. 2019;11(12):1954.
 67. Metro G, Addeo A, Signorelli D, Gili A, Economopoulou P, Roila F, Banna G, De Toma A, Rey Cobo J, Camerini A, Christopoulou A, **Lo Russo G**, Banini M, Galetta D, Jimenez B, Collazo-Lorduy A, Calles A, Baxevasos P, Linardou H, Kosmidis P, Garassino MC, Mountzios G. Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 $\geq 50\%$ who progress on first-line immunotherapy: real-world data from a European cohort. *J Thorac Dis* 2019;11(12):4972-4981.
 68. Nichetti F, Ligorio F, Zattarin E, Signorelli D, Prelaj A, Proto C, Galli G, Marra A, Apollonio G, Porcu L, de Braud F, **Lo Russo G**, Ferrara R, Garassino MC. Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients. *Cancers (Basel)* 2019 25;12(1):67.
 69. Adashek JJ, Kato S, Ferrara R, **Lo Russo G**, Kurzrock R. Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress? *Oncologist* 2020;25(2):94-98.
 70. Beninato T, **Lo Russo G**, Garassino MC, De Braud F, Platania M. Recurrent thrombosis followed by Lazarus response in ROS1 rearranged NSCLC treated with crizotinib: a case report. *Tumori* 2020; 17:300891620905665
 71. Prelaj A, **Lo Russo G**, Proto C, Signorelli D, Ferrara R, Galli G, De Toma A, Randon G, Pagani F, Trevisan B, Ganzinelli M, Zilembo N, Montrone M, Longo V, Pesola F, Pizzutillo P, Del Bene G, Varesano N, Galetta D, Torri V, Garassino MC, Di Maio M, Catino A. DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non-Small-Cell Lung Cancer: An External Validation. *Clin Lung Cancer* 2020; 7:S1525-7304(20)30005-X. (First name, equal contribute to the first author).
 72. Corrao G, Marvaso G, Ferrara R, **Lo Russo G**, Gugliandolo SG, Piperno G, Spaggiari L, De Marinis F, Orecchia R, Garassino MC, Jereczek-Fossa BA. Stereotatic radiotherapy in metastatic non-small cell lung cancer: Combining immunotherapy and radiotherapy with a focus on liver metastases. *Lung Cancer* 2020;142:70-79.
 73. **Lo Russo G**, Facchinetti F, Tiseo M, Garassino MC, Ferrara R. Hyperprogressive Disease upon Immune Checkpoint Blockade: Focus on Non-small Cell Lung Cancer. *Curr Oncol Rep* 2020;22(5):41.
 74. Vernieri C, Ganzinelli M, Rulli E, Farina G, Bettini AC, Bareggi C, Rosso L, Signorelli D, Galli G, **Lo Russo G**, Proto C, Moro M, Indraccolo S, Busico A, Sozzi G, Torri V, Marabese M, Massimo B, Garassino MC; TAILOR trialists. LKB1 mutations are not associated with the efficacy of first-line and second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC): a post hoc analysis of the TAILOR trial. *ESMO Open* 2020;5(3):e000748.
 75. Trama A, Proto C, Signorelli D, Garassino MC, **Lo Russo G**, Ganzinelli M, Prelaj A, Mensi C, Gangemi M, Gennaro V, Chellini E, Caldarella A, Angelillo IF, Ascoli V, Pascucci C, Tagliabue G, Cusimano R, Bella F, Falcini F, Merler E, Masanotti G, Ziino A, Michiara M, Gola G, Storch C, Mangone L, Vitale MF, Cirilli C, Tumino R, Scuderi T, Fanetti AC, Piffer S, Tiseo M, Gatta G, Botta L; LUME study WG. Treatment patterns among patients with malignant pleural mesothelioma: An Italian, population-based nationwide study. *Thorac Cancer* 2020;11(6):1661-1669.
 76. Prelaj A, Proto C, **Lo Russo G**, Signorelli D, Ferrara R, Mensah M, Galli G, De Toma A, Viscardi G, Brambilla M, Lobefaro R, TrevisanB, Trovò F, Torri V, Sozzi G, Garassino MC, Boeri M. Integrating clinical and biological prognostic biomarkers in patients with

- advanced NSCLC treated with immunotherapy: the DEMo score system. *Transl Lung Cancer Res* 2020;9(3):617-628
77. Nichetti F, **Lo Russo G**, Prelaj A, Provenzano L, de Braud F, Cabiddu M, Garassino MC, Petrelli F. ALK/ROS1 rearrangements: A real hallmark for thromboembolic events in cancer patients? *Thrombosis Research* 2020; 194: 176-177.
 78. Friedlaender A, Metro G, Signorelli D, Gili A, Economopoulou P, Roila F, Banna G, De Toma A, Camerini A, Christopoulou A, **Lo Russo G**, Banini M, Galetta D, Jimenez B, Collazo-Lorduy A, Calles A, Baxevanos P, Linardou H, Kosmidis P, Mountzios G, Garassino MC, Addeo A. Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score $\geq 50\%$ treated with front-line pembrolizumab. *Acta Oncologica* 2020; doi.org/10.1080/0284186X.2020.1781249
 79. Facchinetti F, **Lo Russo G**, Tiseo M, Garassino MC, Ferrara R. How to recognize and manage hyper-progression and pseudoprogression during immune checkpoint blockade in non-small cell lung cancer. *Precis Cancer Med* 2019;2:35 <http://dx.doi.org/10.21037/pcm.2019.10.03>.
 80. Ferrara R, Mezquita L, Texier M, Lahmar J, Audigier-Valette C, Tessonier L, Mazieres J, Zalcman G, Brosseau S, Le Moulec S, Leroy L, Duchemann B, Lefebvre C, Veillon R, Westeel V, Koscielny S, Champiat S, Ferte C, Planchard D, Remon J, Boucher ME, Gazzah A, Adam J, **Lo Russo G**, Signorelli D, Garassino MC, Soria JC, Caramella C, Besse B. Comparison of Fast-Progression, Hyperprogressive Disease, and Early Deaths in Advanced Non-Small-Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or Chemotherapy. *JCO Precis Oncol* 2020; 4:829-840.
 81. Alvisi MF, Ganzinelli M, Linardou H, Caiola E, **Lo Russo G**, Cecere FL, Bettini AC, Psyrris A, Milella M, Rulli E, Fabbri A, De Maglie M, Romanelli P, Murray S, Ndembe G, Broggin M, Garassino MC, Marabese M. Predicting the Role of DNA Polymerase α Alone or with KRAS Mutations in Advanced NSCLC Patients Receiving Platinum-Based Chemotherapy. *J Clin Med* 2020, 9, 2438.
 82. Bersanelli M, Buti S, Giannarelli D, Leonetti A, Cortellini A, **Lo Russo G**, Signorelli D, Toschi L, Milella M, Pilotto S, Bria E, Proto C, Marinello A, Randon G, Rossi S, Vita E, Sartori G, D'Argento E, Qako E, Giaiacopi E, Ghilardi L, Bettini AC, Rapacchi E, Mazzoni F, Lavacchi D, Scotti V, Ciccone LP, De Tursi M, Di Marino P, Santini D, Russano M, Bordi P, Di Maio M, Audisio M, Filetti M, Giusti R, Berardi R, Fiordoliva I, Cerea G, Pizzutilo EG, Bearz A, De Carlo E, Cecere F, Renna D, Camisa R, Caruso G, Ficorella C, Banna GL, Cortinovis D, Brighenti M, Garassino MC, Tiseo M. Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study. *Lung Cancer* 2020; 150:123-131.
 83. Mountzios G, de Toma A, Economopoulou P, Friedlaender A, Banini M, **Lo Russo G**, Baxevanos P, Roila F, Banna GL, Christopoulou A, Jimenez B, Collazo-Lorduy A, Linardou H, Calles A, Galetta D, Addeo A, Camerini A, Pizzutilo P, Kosmidis P, Garassino MC, Proto C, Signorelli D, Metro G. Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy. *Clin Lung Cancer* 2020; 14:S1525-7304(20)30297-7.
 84. Ferrara R, Signorelli D, Proto C, Prelaj A, Garassino MC, **Lo Russo G**. Novel patterns of progression upon immunotherapy in other thoracic malignancies and uncommon populations. *Transl Lung Cancer Res* 2020; <http://dx.doi.org/10.21037/tlcr-20-636>
 85. Signorelli D, Proto C, Botta L, Trama A, Tiseo M, Pasello G, **Lo Russo G**, Fabbri A, Imbimbo M, Busico A, Prelaj A, Ferrara R, Galli G, De Toma A, Tamborini E, Pastorino U, de Braud F, Gatta G, Garassino MC, Ganzinelli M. SMO mutations confer poor prognosis in malignant pleural mesothelioma. *Transl Lung Cancer Res* 2020;9(5):1940-1951.
 86. De Toma A, **Lo Russo G**, Signorelli D, Ferrara R, Prelaj A, Galli G, Viscardi G, Trevian B, Ganzinelli M, Zilembo N, de Braud F, Garassino MC, Proto C. Facing the first-line in metastatic non-small-cell lung cancer – Immunotherapy and chemotherapy. *Europ Oncol Haematol* 2020, 16:39-43.
 87. Occhipinti M, Brambilla M, Ferrara R, Manglaviti S, Garassino MC, **Lo Russo G**. Is hyperprogressive disease a specific phenomenon of immunotherapy? *Explor Target Antitumor Ther.* 2020;1:427-433 doi.org/10.37349/etat.2020.00027
 88. Lobefaro R, Viscardi G, Di Liello R, Massa G, Iacovino ML, Sparano F, Della Corte C M, Ferrara R, Signorelli D, Proto C, Prelaj A, Galli G, De Toma A, Brambilla M, Ganzinelli M, Trevisan B, Ciardiello F, De Braud F, Morgillo F, Garassino MC, **Lo Russo G**. Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers. *Lung Cancer* 2021; 152:165-173.
 89. Ganzinelli M, Linardou H, Alvisi MF, Caiola E, **Lo Russo G**, Cecere FL, Bettini AC,

- Psyrrì A, Milella M, Rulli E, Fabbri A, De Maglie M, Romanelli P, Murray S, Brogginì M, Marabese M, Garassino MC. Single-arm, open label prospective trial to assess prediction of the role of ERCC1/XPF complex in the response of advanced NSCLC patients to platinum-based chemotherapy. *ESMO Open* 2021
90. Prinzi N, Rossi RE, Proto C, Leuzzi G, Raimondi A, Torchio M, Milione M, Corti F, Colombo E, Prisciandaro M, Cascella T, Spreafico C, Beninato T, Coppa J, **Lo Russo G**, Di Bartolomeo M, de Braud F, Pusceddu S. Recent Advances in the Management of Typical and Atypical Lung Carcinoids. *Clin Lung Cancer*. 2020 Dec 17:S1525-7304(20)30347-8.
 91. Prelaj A, Pircher CC, Massa G, Martelli V, Corrao G, **Lo Russo G**, Proto C, Ferrara R, Galli G, De Toma A, Genova C, Jereczek-Fossa BA, de Braud F, Garassino MC, Rebuzzi SE, Beyond First-Line Immunotherapy: Potential Therapeutic Strategies Based on Different Pattern Progressions: Oligo and Systemic Progression. *Cancers* 2021, 13, 1300. <https://doi.org/10.3390/cancers13061300>
 92. Banna GL, Cortellini A, Cortinovis DL, Tiseo M, Aerts JGJV, Barbieri F, Giusti R, Bria E, F. Grossi, Pizzutilo P, Berardi R, Morabito A, Genova C, Mazzoni F, Di Noia V, Signorelli D, Gelibter A, Macerelli M, Rastelli F, Chiari R, Rocco D, Gori S, De Tursi M, Di Marino P, Mansueto G, Zoratto F, Filetti M, Montrone M, Citarella F, Marco R, Cantini L, Nigro O, D'Argento E, Buti S, Minuti G, Landi L, Guaitoli G, **Lo Russo G**, De Toma A, Donisi C, Friedlaender A, De Giglio A, Metro G, Porzio G, Ficorella C, Addeo A. The lung immunology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 $\geq 50\%$ advanced non-small-cell lung cancer. *ESMO OPEN* 2021, 6 (2) 1-9
 93. De Toma A, **Lo Russo G**, Signorelli D, Pagani F, Randon G, Galli G, Prelaj A, Ferrara R, Proto C, Ganzinelli M, Zilembo N, de Braud F, Garassino MC. Uncommon targets in non-small cell lung cancer: everyone wants a slice of cake. *Crit Rev Oncol Hematol*. 2021, 12:103299. doi: 10.1016/j.critrevonc.2021.103299. (First name, equal contribute to the first author).
 94. Prelaj A, Bottiglieri A, Proto C, **Lo Russo G**, Signorelli D, Ferrara R, Galli G, De Toma A, Viscardi G, Brambilla M, Lobefaro R, Nichetti F, Manglaviti S, Occhipinti M, Labianca A, Ganzinelli M, Gallucci R, Zilembo N, Greco GF, Torri V, de Braud F, Garassino MC. Pozotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program. *Eur J Cancer*. 2021 2:S0959-8049(21)00146-5. doi: 10.1016/j.ejca.2021.02.038.
 95. Occhipinti M, Brambilla M, Galli G, Manglaviti S, Giammaruco M, Prelaj A, Ferrara R, De Toma A, Proto C, Beninato T, Zattarin E, **Lo Russo G**, Gelibter AJ, Simmaco M, Preissner R, Garassino MC, De Braud F, Marchetti P. Evaluation of Drug—Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors. *J. Pers. Med*. 2021, 11(5), 424
 96. Bertolini G, Cancila V, Milione M, **Lo Russo G**, Fortunato O, Zaffaroni N, Tortoreto M, Centonze G, Chiodoni C, Facchinetti F, Pollaci G, Taiè G, Giovino F, Moro M, Camisaschi C, De Toma A, D'Alterio C, Pastorino U, Tripodo C, Scala S, Sozzi G, Roz L. A novel CXCR4 antagonist counteracts paradoxical generation of cisplatin-induced prometastatic niches in lung cancer. *Mol Ther* 2021; 20:S1525-0016(21)00266-5
 97. Manglaviti S, Brambilla M, Signorelli D, Ferrara R, **Lo Russo G**, Proto C, Galli G, De Toma A, Occhipinti M, Viscardi G, Beninato T, Zattarin E, Bini M, Lobefaro R, Massa G, Bottiglieri A, Apollonio G, Sottotetti E, Di Mauro RM, Trevisan B, Ganzinelli M, Fabbri A, de Braud FGM, Garassino MC, Prelaj A. Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology. *Clin Lung Cancer*. 2021 Jul 5:S1525-7304(21)00180-7. doi: 10.1016/j.clcc.2021.06.013.
 98. Prelaj A, Boeri M, Robuschi A, Ferrara R, Proto C, **Lo Russo G**, Galli G, De Toma A, Brambilla M, Occhipinti M, Manglaviti S, Beninato T, Bottiglieri A, Massa G, Zattarin E, Gallucci R, Galli E, Ganzinelli M, Sozzi G, de Braud F, Garassino MC, Restelli M, Pedrocchi A, Trovo' F. Machine Learning Using Real-World and Translational Data to Improve Treatment Selection for NSCLC Patients Treated with Immunotherapy. *Cancers* 2022, 14, 435. <https://doi.org/10.3390/cancers14020435>
 99. Whisenant JG, Baena J, Cortellini A, Huang LC, **Lo Russo G**, Porcu L, Wong SK, Bestvina CM, Hellmann MD, Roca E, Rizvi H, Monnet I, Boudjemaa A, Rogado J, Pasello G, Leighl NB, Arrieta O, Aujayeb A, Batra U, Azzam AY, Unk M, Azab MA, Zhumagaliyeva AN, Gomez-Martin C, Blaquier JB, Geraedts E, Mountzios G, Serrano-Montero G, Reinmuth N, Coate L, Marmarelis M, Presley CJ, Hirsch FR, Garrido P, Khan H, Baggi A, Mascaux C, Halmos B, Ceresoli GL, Fidler MJ, Scotti V, Métévier AC, Falchero L, Felip E, Genova C, Mazieres J, Tapan U, Brahmer J, Bria E, Puri S, Popat S, Reckamp KL, Morgillo F, Nadal E, Mazzoni F, Agustoni F, Bar J, Grosso F, Avrillon V, Patel JD, Gomes

- F, Ibrahim E, Trama A, Bettini AC, Barlesi F, Dingemans AM, Wakelee H, Peters S, Horn L, Garassino MC, Torri V; TERA-VOLT study group. A definitive prognostication system for patients with thoracic malignancies diagnosed with COVID-19: an update from the TERA-VOLT registry. *J Thorac Oncol* 2022. 24:S1556-0864(22)00033-8. doi: 10.1016/j.jtho.2021.12.015.
100. Zanella C, Leone AG, Zambelli L, Bottiglieri A, Canziani L, Brambilla M, **Lo Russo G**, Platania M, De Braud F, Occhipinti M. Paraneoplastic neurological syndrome in patients affected by SCLC: a case series. *Tumori*. 2022 Mar 8;3008916221079663.
 101. Vismara M, Reduzzi C, Silvestri M, Murianni F, **Lo Russo G**, Fortunato O, Motta R, Lanzoni D, Giovino F, Miodini P, Pasquali S, Suatoni P, Pastorino U, Roz L, Sozzi G, Cappelletti V, Bertolini G. Single-Cell Phenotypic and Molecular Characterization of Circulating Tumor Cells Isolated from Cryopreserved Peripheral Blood Mononuclear Cells of Patients with Lung Cancer and Sarcoma. *Clin Chem*. 2022 Mar 19:hvac019.
 102. Cantini L, Mentrasti G, **Lo Russo G**, Signorelli D, Pasello G, Rijavec E, Russano M, Antonuzzo L, Rocco D, Giusti R, Adamo V, Genova C, Tuzi A, Morabito A, Gori S, Verde NL, Chiari R, Cortellini A, Cognigni V, Pecci F, Indini A, De Toma A, Zattarin E, Oresti S, Pizzutilo EG, Frega S, Erbetta E, Galletti A, Citarella F, Fancelli S, Caliman E, Della Gravara L, Malapelle U, Filetti M, Piras M, Toscano G, Zullo L, De Tursi M, Di Marino P, D'Emilio V, Cona MS, Guida A, Caglio A, Salerno F, Spinelli G, Bennati C, Morgillo F, Russo A, Dellepiane C, Vallini I, Sforza V, Inno A, Rastelli F, Tassi V, Nicolardi L, Pensieri V, Emili R, Roca E, Migliore A, Galassi T, Rocchi MLB, Berardi R. Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario. *ESMO Open*. 2022 Feb 3;7(2):100406.
 103. Zattarin E, Manglaviti S, Apollonio G, Beninato T, Mazzeo L, Massa G, Bottiglieri A, Galli E, De Toma A, Occhipinti M, Brambilla M, Ferrara R, Ganzinelli M, Proto C, Garassino MC, de Braud F, **Lo Russo G**, Prelaj A. Prognostic role of neutrophil-to-lymphocyte ratio and EPSiLoN score in advanced non-small-cell lung cancer patients treated with first-line chemo-immunotherapy. *Future Oncol* 2022; 18(23):2593-2604. (Last name, equal contribute to the last author).
 104. Prelaj A, Bottiglieri A, Bhat G, Washington R, Calareso G, Greco GF, Ferrara R, Brambilla M, De Toma A, Occhipinti M, Manglaviti S, Soro A, Ganzinelli M, **Lo Russo G**, Proto C. Case Report: Exceptional Response to Poziotinib in Patient with Metastatic Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutation. *Front Oncol*. 2022 Jun 8;12:902967.
 105. Antonarelli G, Corti C, Zucali PA, Perrino M, Manglaviti S, **Lo Russo G**, Varano GM, Salvini P, Curigliano G, Catania C, Conforti F, De Pas T. Continuous sunitinib schedule in advanced platinum refractory thymic epithelial neoplasms: A retrospective analysis from the ThYmic MalignancIEs (TYME) Italian collaborative group. *Eur J Cancer*. 2022 Aug 12;174:31-36.
 106. Galli G, Corsetto PA, Proto C, **Lo Russo G**, Ganzinelli M, Rulli E, Legramandi L, Morelli D, Ferrara R, Prelaj A, Signorelli D, De Toma A, Brambilla M, Occhipinti M, Manglaviti S, Boeri M, Martinetti A, Vingiani A, Colombo MP, Rizzo AM, Torri V, de Braud F, Sangaletti S, Sica A, Garassino MC. Circulating Fatty Acid Profile as a Biomarker for Immunotherapy in Advanced Non-Small Cell Lung Cancer. *Clin Lung Cancer*. 2022 Jul 21:S1525-7304(22)00155-3.
 107. Signorelli D, Ghidotti P, Proto C, Brambilla M, De Toma A, Ferrara R, Galli G, Ganzinelli M, **Lo Russo G**, Prelaj A, Occhipinti M, Viscardi G, Capizzuto V, Pontis F, Petrarola I, Ferretti AM, Colombo MP, Torri V, Sozzi G, Garassino MC, Jachetti E, Fortunato O. Circulating CD81-expressing extracellular vesicles as biomarkers of response for immune-checkpoint inhibitors in advanced NSCLC. *Front Immunol*. 2022 Sep 20;13:987639. doi: 10.3389/fimmu.2022.987639. eCollection 2022.
 108. Viscardi G, Tralongo AC, Massari F, Lambertini M, Mollica V, Rizzo A, Comito F, Di Liello R, Alfieri S, Imbimbo M, Della Corte CM, Morgillo F, Simeon V, **Lo Russo G**, Proto C, Prelaj A, De Toma A, Galli G, Signorelli D, Ciardiello F, Remon J, Chaput N, Besse B, de Braud F, Garassino MC, Torri V, Ciniquini M, Ferrara R. Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis. *Eur J Cancer*. 2022 Oct 5;177:175-185.
 109. Passaro A, **Lo Russo G**, Passiglia F, D'Arcangelo M, Sbrana A, Russano M, Bonanno L, Giusti R, Metro G, Bertolini F, Grisanti S, Carta A, Cecere F, Montrone M, Massa G, Perrone F, Simionato F, Guaitoli G, Scotti V, Genova C, Lugini A, Bonomi L, Attili I, de Marinis F. Pralsetinib in RET fusion-positive non-small-cell lung cancer: A real-world data (RWD) analysis from the Italian expanded access program (EAP). *Lung Cancer*. 2022

110. **G Lo Russo**, F Sgambelluri, A Prelaj, F Galli, S Manglaviti, A Bottiglieri, RM Di Mauro, R Ferrara, G Galli, D Signorelli, A De Toma, M Occhipinti, M Brambilla, E Rulli, T Triulzi, T Torelli, L Agnelli, S Brich, A Martinetti, AD Dumitrascu, V Torri, G Pruner, A Fabbri, F de Braud, A Anichini, C Proto, M Ganzinelli, R Mortarini, MC Garassino. PEOPLE (NTC03447678) a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkers. ESMO Open 2022;7(6):100645.
111. G Mountzios, D Planchard, G Metro, D Tsiouda, A Prelaj, S Lampaki, W Shalata, M Riudavets, P Christopoulos, N Girard, V Albarrán-Artahona, RG Campelo, K Samitas, GL Banna, I Boukovinas, A Agbarya, A Koumariou, EI Perdikouri, P Kosmidis, H Linardou, D Mauri, D Mavroudis, I Athanasiadis, H Kalofonos, N Xenidis, I Korantzis, A Ardavanis, G Rallis, A Bottiglieri, K Efthymiadis, G Oikonomopoulos, A Kokkalis, E Saloustros, N Tsoukalas, D Bartz, P Economopoulou, A Psyrris, M Reck, **G Lo Russo**. Molecular Epidemiology and Treatment Patterns of Patients With EGFR Exon 20-Mutant NSCLC in the Precision Oncology Era: The European EXOTIC Registry. JTO Clin Res Rep 2022; 4, 1: 100433.
112. Prelaj A, Galli EG, Miskovic V, Pesenti M, Viscardi G, Pedica B, Mazzeo L, Bottiglieri A, Provenzano L, Spagnoletti A, Marinacci R, De Toma A, Proto C, Ferrara R, Brambilla M, Occhipinti M, Manglaviti S, Galli G, Signorelli D, Giani C, Beninato T, Pircher CC, Rametta A, Kosta S, Zanitti M, Di Mauro MR, Rinaldi A, Di Gregorio S, Antonia M, Garassino MC, de Braud FGM, Restelli M, **Lo Russo G**, Ganzinelli M, Trovò F, Pedrocchi ALG. Real-world data to build explainable trustworthy artificial intelligence models for prediction of immunotherapy efficacy in NSCLC patients. Front Oncol 2023; 12:1078822.
113. Prelaj A, Ganzinelli M, Trovò F, Roisman LC, Pedrocchi ALG, Kosta S, Restelli M, Ambrosini E, Broggin M, Pravettoni G, Monzani D, Nuara A, Amat R, Spathas N, Willis M, Pearson A, Dolezal J, Mazzeo L, Sangaletti S, Correa AM, Aguaron A, Watermann I, Popa C, Raimondi G, Triulzi T, Steurer S, **Lo Russo G**, Linardou H, Peled N, Felip E, Reck M, Garassino MC. The EU-funded I3LUNG Project: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy. Clin Lung Cancer. 2023 Feb 28:S1525-7304(23)00039-6.
114. Cantini L, Paoloni F, Pecci F, Spagnolo F, Genova C, Tanda ET, Aerts S, Rebuzzi SE, Fornarini G, Zoratto F, Fancelli S, Lupi A, Della Corte CM, Parisi A, Bennati C, Ortega C, Atzori F, Piovano PL, Orciuolo C, De Tursi M, Ghidini M, Botticelli A, Scagnoli S, Belluomini L, Leporati R, Veccia A, Di Giacomo AM, Festino L, Cortinovis D, Acquati M, Filetti M, Giusti R, Tucci M, Sergi MC, Garutti M, Puglisi F, Manglaviti S, Citarella F, Santoni M, Rijavec E, **Lo Russo G**, Santini D, Addeo A, Antonuzzo L, Indini A, Rocchi MBL, Cortellini A, Grossi F, Ascierto PA, Aerts JGJV, Berardi R. Safety of Extended interval Dosing Immune Checkpoint Inhibitors: a multicentre cohort study. J Natl Cancer Inst.
115. Proto C, Manglaviti S, **Lo Russo G**, Musca M, Galli G, Imbimbo M, Perrino M, Cordua N, Rulli E, Ballatore Z, Maso AD, Chella A, Sbrana A, Prelaj A, Ferrara R, Occhipinti M, Brambilla M, De Toma A, Mazzeo L, Beninato T, Signorelli D, Massa G, Greco FG, Calareso G, Miliziano D, Di Mauro RM, Mella G, Lucarelli A, Paggio A, Galli F, Torri V, de Braud FGM, Pasello G, Petrini I, Berardi R, Ganzinelli M, Garassino MC, Zucali PA. STYLE (NCT03449173): A Phase 2 Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines. J Thorac Oncol. 2023 Apr 23:S1556-0864(23)00513-0.
116. **Lo Russo G**, Prelaj A, Dolezal J, Beninato T, Agnelli L, Triulzi T, Fabbri A, Lorenzini D, Ferrara R, Brambilla M, Occhipinti M, Mazzeo L, Provenzano L, Spagnoletti A, Viscardi G, Sgambelluri F, Brich S, Miskovic V, Pedrocchi ALG, Trovò F, Manglaviti S, Giani C, Ambrosini P, Leporati R, Franza A, McCulloch J, Torelli T, Anichini A, Mortarini R, Trinchieri G, Pruner G, Torri V, De Braud F, Proto C, Ganzinelli M, Garassino MC. PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis. J Immunother Cancer. 2023 Jun;11(6):e006833
117. Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Gao S, Chen KN, Dooms C, Majem M, Eigendorff E, Martinengo GL, Bylicki O, Rodríguez-Abreu D, Chaft JE, Novello S, Yang J, Keller SM, Samkari A, Spicer JD; KEYNOTE-671 Investigators. Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer. N Engl J Med. 2023 Aug 10;389(6):491-503. (**KEYNOTE-671 Investigators**).
118. Brambilla M, Beninato T, Piemontese A, Mazzeo L, Pircher CC, Manglaviti S, Ambrosini P, Signorelli D, Lorenzini D, Prelaj A, Ferrara R, Proto C, **Lo Russo G**, Pizzutillo EG, Ganzinelli M, Grande I, Capone I, Di Mauro RM, Conca E, Dumitrascu AD, Zanella C,

- Leporati R, Rota S, Garassino MC, Marchetti P, de Braud FM, Occhipinti M. Exploring the Role of Immunotherapy-Based Treatments for Advanced Non-Small-Cell Lung Cancer With Novel Driver Alterations. *Clin Lung Cancer*. 2023 23:S1525-7304(23)00149-3.
119. Pecci F, Cantini L, Cognigni V, Perrone F, Mazzaschi G, Agostinelli V, Mentrasti G, Favari E, Maffezzoli M, Cortellini A, Rossi F, Chiariotti R, Venanzi FM, **Lo Russo G**, Galli G, Proto C, Ganzinelli M, Tronconi F, Morgese F, Campolucci C, Moretti M, Vignini A, Tiseo M, Minari R, Rocchi MLB, Buti S, Berardi R. Prognostic Impact of Blood Lipid Profile in Patients With Advanced Solid Tumors Treated With Immune Checkpoint Inhibitors: A Multicenter Cohort Study. *Oncologist*. 2023 Oct 5:oyad273.
 120. Manglaviti S, Bini M, Apollonio G, Zecca E, Galli G, Sangaletti S, Labianca A, Sottotetti E, Brambilla M, Occhipinti M, Proto C, Prelaj A, Signorelli D, De Toma A, Viscardi G, Beninato T, Mazzeo L, Bottiglieri A, Leporati R, Fotia G, Ganzinelli M, Portararo P, Garassino MC, de Braud FGM, **Lo Russo G**, Torri V, Ferrara R. High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors. *Lung Cancer*. 2023 Oct 29;186:107417.
 121. Chu Q, Perrone F, Greillier L, Tu W, Piccirillo MC, Grosso F, **Lo Russo G**, Florescu M, Mencoboni M, Morabito A, Cecere FL, Ceresoli GL, Dawe DE, Zucali PA, Pagano M, Goffin JR, Sanchez ML, Gridelli C, Zalcman G, Quantin X, Westeel V, Gargiulo P, Delfanti S, Tu D, Lee CW, Leigh N, Sederias J, Brown-Walker P, Luo Y, Lantuejoul S, Tsao MS, Scherpereel A, Bradbury P, Laurie SA, Seymour L. Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial. *Lancet*. 2023 Nov 3:S0140-6736(23)01613-6.
 122. Lim SM, Peters S, Ortega Granados AL, Pinto GDJ, Fuentes CS, **Lo Russo G**, Schenker M, Ahn JS, Reck M, Szigyarto Z, Huseinovic N, Zografos E, Buss E, Stjepanovic N, O'Donnell S, de Marinis F. Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trial. *Nat Commun*. 2023 Nov 11;14(1):7301.
 123. A. Prelaj, V. Miskovic, M. Zanitti, F. Trovo, C. Genova, G. Viscardi, S. E. Rebuzzi, L. Mazzeo, L. Provenzano, S. Kosta, M. Favali, A. Spagnoletti, L. Castelo-Branco, J. Dolezal, A. T. Pearson, **G. Lo Russo**, C. Proto, M. Ganzinelli, C. Giani, E. Ambrosini, S. Turajlic, L. Au, M. Koopman, S. Delaloge, J. N. Kather, F. de Braud, M. C. Garassino, G. Pentheroudakis, C. Spencer, A. L. G. Pedrocchi. Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review. *Ann Oncol*. 2023
 124. F Passiglia, ML Reale, **G Lo Russo**, G Pasello, G Minuti, A Bulotta, D Galetta, G Pelizzari, C Sini, E Bria, E Roca, S Pilotto, C Genova, G Metro, F Citarella, R Chiari, D Cortinovis, A Delmonte, A Russo, M Tiseo, G Cerea, A Carta, T Scotti, T Vaval, M Brambilla, L Buffoni, R Buosi, C Catania, S Gori, S Grisanti, F Agustoni, E Garbo, U Malapelle, S Novello. Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access program. *Lung Cancer* 187 (2024) 107444
 125. **Lo Russo G**, Bironzo P, Bennati C, Bonanno L, Catino A, Metro G, Petrini I, Russano M, Passaro A. Clinical evidence and adverse event management update of patients with RET- rearranged advanced non-small-cell lung cancer (NSCLC) treated with pralsetinib. *Crit Rev Oncol Hematol*. 2023 Dec 20;194:104243.
 126. A Prelaj, M Ganzinelli, L Provenzano, L Mazzeo, G Viscardi, G Metro, G Galli, F Agustoni, CM Della Corte, A Spagnoletti, C Giani, R Ferrara, C Proto, M Brambilla, AD Dumitrascu, A Inno, D Signorelli, EG Pizzutilo, M Brighenti, F Biello, C Bennati, L Toschi, M Russano, A Cortellini, C Catania, F Bertolini, R Berardi, L Cantini, F Pecci, M Macerelli, R Emili, C Bareggi, F Verderame, A Lugini, S Pisconti, F Buzzacchino, M Aieta, A Tartarone, G Spinelli, E Vita, S Grisanti, F Trovò, P Auletta, D Lorenzini, L Agnelli, S Sangaletti, F Mazzoni, G Calareso, M Ruggirello, GF Greco, R Vigorito, M Occhipinti, S Manglaviti, T Beninato, R Leporati, P Ambrosini, R Serino, C Silvestri, E Zito, ACL Pedrocchi, V Miskovic, F de Braud, G Pruneri, **G Lo Russo**, C Genova, A Vingiani. APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research. *Clin Lung Canc* 2024
 127. Cerbone L, Delfanti S, Crivellari S, De Angelis AM, Mazzeo L, Proto C, Occhipinti M, **Lo Russo G**, Dellepiane C, Biello F, Alabiso I, Verderame F, Gauna R, De Simone I, Cuppone F, Petraglia S, Pasello G, Ceresoli GL, Garassino MC, Torri V, Grosso F. Nivolumab in pretreated pleural mesothelioma: Results from an observational real-world study of patients treated within the AIFA 5% Fund. *Tumori*. 2024
 128. Leporati R, Miliziano D, Beninato T, Mazzeo L, Manglaviti S, Brambilla M, Occhipinti M, Prelaj A, Proto C, **Lo Russo G**. Response to lorlatinib rechallenge in a case of ALK-

- rearranged metastatic NSCLC with a resistance mutation to second generation TKIs. Tumori. 2024
129. Miceli R, Eriksson H, **Lo Russo G**, Alfieri S, Moksnes Bjaanæs M, Pietrantonio F, De Cecco L, Prelaj A, Proto C, Franzén J, McDonnell D, Berenguer Pina JJ, Beninato T, Mazzeo L, Giannatempo P, Verzoni E, Crown J, Helland Å, Eustace A. Gender Difference in side Effects of Immunotherapy: a possible clue to optimize cancer treatment (G-DEFINER): study protocol of an observational prospective multicenter study. Acta Oncol. 2024 Apr 21;63:213-219.
 130. Proto C, Ganzinelli M, Manglaviti S, Imbimbo M, Galli G, Marabese M, Zollo F, Alvisi MF, Perrino M, Cordua N, Borea F, de Vincenzo F, Chella A, Cappelli S, Pardini E, Ballatore Z, Lucarelli A, Ambrosini E, Giuliano M, Pietroluongo E, Mulargiu C, Fabbri A, Prelaj A, Occhipinti M, Brambilla M, Mazzeo L, Beninato T, Vigorito R, Ruggirello M, Greco FG, Calareso G, Miliziano D, Rulli E, De Simone I, Torri V, de Braud FGM, Pasello G, De Placido P, Berardi R, Petrini I, Zucali P, Garassino MC, **Lo Russo G**. Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVANT phase II trial (NCT03921671). Ann Oncol. 2024 Jun 8:S0923-7534(24)00724-5.
 131. Beninato T, **Lo Russo G**, Leporati R, Roz L, Bertolini G. Circulating tumor cells in lung cancer: Integrating stemness and heterogeneity to improve clinical utility. Int Rev Cell Mol Biol. 2025;392:1-66.
 132. Occhipinti M, Brambilla M, Di Liello R, Ambrosini P, Lobianco L, Leporati R, Salvatore M, Vitiello F, Marchesi S, Manglaviti S, Beninato T, Mazzeo L, Proto C, Prelaj A, Ferrara R, Della Corte CM, **Lo Russo G**, de Braud F, Ganzinelli M, Viscardi G. Unleashing precision: a review of targeted approaches in pleural mesothelioma. Crit Rev Oncol Hematol. 2024
 133. Filetti M, Occhipinti M, Cirillo A, Scirocchi F, Ugolini A, Giusti R, Lombardi P, Daniele G, Botticelli A, **Lo Russo G**, De Braud F, Marchetti P, Nuti M, Ferretti E, Farina L, Rughetti A, Petti M. Exploring genomic biomarkers for pembrolizumab response: a real-world approach and patient similarity network analysis reveal DNA response and repair gene mutations as a signature. Cancers. 2024, 16, 3955.
 134. Spicer JD, Garassino MC, Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Chen KN, Doms C, Majem M, Eigendorff E, Martinengo GL, Bylicki O, Rodríguez-Abreu D, Chaff JE, Novello S, Yang J, Arunachalam A, Keller SM, Samkari A, Gao S; KEYNOTE-671 Investigators. Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2024 Sep 28;404(10459):1240-1252(**KEYNOTE-671 Investigators**).
 135. Ambrosini P, Miliziano D, Liberti GD, Lorenzini D, Marchesi S, Bassetti A, Tamborini E, Leporati R, Beninato T, Mazzeo L, Brambilla M, Ganzinelli M, Prelaj A, Proto C, Braud FG, **Lo Russo G**, Occhipinti M. Histologic Transformation of ALK-Rearranged Lung Adenocarcinomas to High-Grade LCNEC: Clinical and Molecular Description of Three Cases. Clin Lung Cancer. 2024 Nov 25:S1525-7304(24)00256-0.
 136. Leporati R, Auclin É, Morchón D, Ferriol-Galmés M, Laguna JC, Gorria T, Teixidó C, Aranzazu Amores M, Ambrosini P, Isla D, **Lo Russo G**, Mezquita L. Sex differences in patients with Non-Small Cell Lung Cancer harboring driver fusions treated with tyrosine kinase inhibitors: a systematic review. Ther Adv Med Oncol. 2024 Dec 17;16:17588359241306940.
 137. Urtecho SB, Provenzano L, Spagnoletti A, Bottiglieri A, Pircher C, Massa G, Sposetti C, Proto C, Brambilla M, Occhipinti M, Mazzeo L, Beninato T, Leporati R, Giani C, Cavalli C, Serino R, Prina MM, Bassetti A, Nasca V, di Mauro RM, Abate A, Manglaviti S, Dumitrascu AD, Liberti GD, Cassano TS, Ganzinelli M, Wu S, Garassino MC, de Braud FGM, **Lo Russo G**, Prelaj A. Decoding KRAS mutation in non-small cell lung cancer patients receiving immunotherapy: A retrospective institutional comparison and literature review. Lung Cancer. 2024
 138. Sebrì V, Dorangricchia P, Monzani D, Marzorati C, Grasso R, Conti L, **G Lo Russo**, Provenzano L, Dumitrascu AD, Pravettoni G. The Implementation of Decision Aids During Medical Consultations for Lung Cancer Patients: A Focus Group Within I3LUNG Project. J Cancer Educ. 2025
 139. Catania C, Manglaviti S, Zucali P, Perrino M, Ruffini E, Di Tommaso L, Mazzella A, Spaggiari L, Delmonte A, **Lo Russo G**, Garassino M, Solli P, Pasello G, Rosso L, Lococo F, Rindi G, Ricciardi S, Picozzi F, Lyberis P, Tinterri B, Pala L, Conforti F, De Pas T. The Rare Entity of Basaloid Thymic Carcinoma: A Multicentric Retrospective Analysis from the Italian Collaborative Group for Thymic Malignancies (TYME). Cancers (Basel). 2025 ;17(2):239

140. Cortellini A, Brunetti L, Di Fazio GR, Garbo E, Pinato DJ, Naidoo J, Katz A, Loza M, Neal JW, Genova C, Gettinger S, Kim SY, Jayakrishnan R, El Zarif T, Russano M, Pecci F, Di Federico A, Awad M, Alessi JV, Montrone M, Owen DH, Signorelli D, Fidler MJ, Li M, Camerini A, De Giglio A, Young L, Vincenzi B, Metro G, Passiglia F, Yendamuri S, Guida A, Ghidini M, Awosika NO, Napolitano A, Fulgenzi CAM, Grisanti S, Grossi F, D'Incecco A, Josephides E, Van Hemelrijck M, Russo A, Gelibter A, Spinelli G, Verrico M, Tomasik B, Giusti R, Newsom-Davis T, Bria E, Sebastian M, Rost M, Forster M, Mukherjee U, Landi L, Mazzoni F, Aujayeb A, Dupont M, Curioni-Fontecedro A, Chiari R, Pantano F, Morabito A, Leonetti A, Friedlaender A, Addeo A, Zoratto F, De Tursi M, Cantini L, Roca E, Mountzios G, Della Gravara L, Kalvapudi S, Inno A, Bironzo P, Di Marco Barros R, O'Reilly D, Bell J, Karapanagiotou E, Monnet I, Baena J, Macerelli M, Majem M, Agustoni F, Cortinovis DL, Tonini G, Minuti G, Bennati C, Mezquita L, Gorria T, Servetto A, Beninato T, **Lo Russo G**, Rogado J, Moliner L, Biello F, Aboubakar Nana F, Dingemans AM, Aerts JGJV, Ferrara R, Torri V, Hejleh TA, Takada K, Naqash AR, Garassino M, Peters S, Wakelee H, Nassar AH, Ricciuti B. Determinants of 5-year survival in patients with advanced NSCLC with PD-L1 $\geq$ 50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry. *J Immunother Cancer*. 2025;13(2):e010674.
141. Esposito D, Ascione CM, Belli S, Napolitano F, Servetto A, Pepe F, Malapelle U, Iaccarino A, Troncone G, Barone D, Bria E, Ferrara R, Lorenzini D, **Lo Russo G**, Ghigna MR, Marinello A, Aldea M, Besse B, Formisano L, Bianco R. AP1-mediated reprogramming of EGFR expression triggers resistance to BLU-667 and LOXO-292 in RET-rearranged tumors. *J Exp Clin Cancer Res*. 2025 May 22;44(1):154.
142. Chiaruttini MV, Proto C, **Lo Russo G**, Prelaj A, Segale M, Zanghì A, Galli F, Greco FG, Signorelli D, Brambilla M, Occhipinti M, De Braud F, Garassino MC, Sozzi G, Rulli E, Boeri M. Tracking the Response to Immunotherapy: Blood microRNA Dynamics in Patients With Advanced Non-Small Cell Lung Cancer. *JCO Precis Oncol*. 2025 May;9:e2400790.
143. Mazzeo, L.;Corso, F.;Baili, P.;Scotti, F.;Torri, V.;Ganzinelli, M.;Mišković, V.;Leporati, R.;Provenzano, L.;Spagnoletti, A.;Silvestri, C.;Giani, C.;Cavalli, C.;di Mauro, R. M.;Meazza Prina, M.;Proto, C.;Brambilla, M.;Occhipinti, M.;Manglaviti, S.;Beninato, T.;Miliziano, D.;Dumitrascu, A. D.;Di Liberti, G.;Cassano, T. S.;de Braud, F. G. M.; **Lo Russo G**; Cappozzo, A.;Paganoni, A. M.;Ieva, F.;Prelaj, A. Data analytics for real-world data integration in TKI-treated NSCLC patients using electronic health records. *ESMO Real World Data and Digital Oncology*. 2025.
144. B. Pongiglione, M. Cucciniello, F. Petracca, O. Ciani, S. Novello, M. Migliorino, P. Pedrazzoli, F. Agustoni, **G. Lo Russo**, R. Tarricone, E. Capelletto. A mobile supportive care app for patients with metastatic lung cancer: the Lung Cancer App (LuCApp) randomized controlled trial. *Supportive Care in Cancer* (2025) 33:641
145. Marchesi S, Marinello A, Ambrosini P, Cavalli C, **Lo Russo G**, Occhipinti M. Immune-checkpoint targeting drug conjugates: a novel class of promising therapeutic agents for cancer treatment. *NPJ Precis Oncol*. 2025 Jul 2;9(1):219.
146. Ambrosini P, Stanzi A, **Lo Russo G**, Solli P, Occhipinti M. Towards a new approach in pleural mesothelioma: perioperative immunotherapy and its implication. *Crit Rev Oncol Hematol* 2025 Jul 23;215:104864.
147. Filippi AR, Rulli E, Signorelli D, Willmann S, Durham A, De Simone I, Santoni A, Galli F, Carlucci L, Torri V, **Lo Russo G**, Addeo A, Guckenberger M. Rationale and Design of the AUSTRAL trial: An Open-Label, Multicenter, Phase II Study Evaluating Radiotherapy Followed by Durvalumab (MEDI4736) and Ceralasertib (AZD6738) in Stage III NSCLC Patients With Thoracic Relapses and/or Oligometastases After the PACIFIC Regimen. *Clinical Lung Cancer*, 2025.
148. F Barlesi, W Yao, M Duruisseaux, L Doucet, A Azkárte Martínez, V Gregorc, OJuañ-Vidal, S Lu, C De Bondt, F de Marinis, H Linardou, YC Kim, R Jotte, E Felip, **G Lo Russo**, M Reck, M F Michenzie, W Yang, J N Meade, B Korytowsky, TSK Mok, for the KRYSTAL-12 Investigators†. Adagrasib versus docetaxel in KRASG12C-mutated non-small cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial. *Lancet* 2025; 406: 615–26.
149. L. Provenzano, M. Favali, L. Mazzeo, A. Spagnoletti, M. Ruggirello, G. Calareso, F. G. Greco, R. Vigorito, A. Quarta, F. Calimeri, M. Monteleone, G. Baselli, E. De Momi, B. Guirges, A. Di Lello, A. Zec, A. Ferrarin, C. Giani, C. Silvestri, M. Occhipinti, M. Brambilla, R. Leporati2, S. Manglaviti, C. Cavalli, G. Mazzoli, D. Miliziano, G. Di Liberti, B. M. Marino, S. Frasca, R. Di Mauro, A. D. Dumitrascu, T. Beninato, C. Proto, M. Ganzinelli, A. Vingiani, D. Lorenzini, C. Agosta, M. Borraccino, C. Bonalume, V. Bartolomeo, R. Romanò, P. Solli, A. R. Filippi, S. Sangaletti, M. Restelli, A. Marchianò, M. C. Garassino,

F. de Braud, F. Trovò, A. L. G. Pedrocchi, **G. Lo Russo**, V. Miskovic, A. Prelaj. Integrating radiomics and real-world data to predict immune checkpoint inhibitor efficacy in advanced non-small-cell lung cancer. *ESMO Real World Data and Digital Oncology* 2025.
150.

PAPERS NON INDEXED FOR MEDLINE *

ORAL PRESENTATIONS

About 50 national and international oral presentations focusing on thoracic neoplasms.

The main:

- Vienna WCLC 2016. Nivolumab in never smoker patients with advanced squamous NSCLC: results from the Italian Expanded Access Programme (EAP).
- Barcellona 10/09/2019. WCLC 2019. Hyperprogressive Disease in advanced Non-small Cell Lung Cancer patients treated with immune checkpoint inhibitors. Oral presentation.
- Barcellona 29/09/2019. ESMO 2019. Poster discussion 1740 PD – 1741 PD – 1742 PD – LBA 093. DISCUSSANT
- Vienna 2-3/10/2020 (Virtual Conference). 7th Immunotherapy of Cancer Conference-ITOC7. Hyperprogressive disease in patients treated with Immune checkpoint inhibitors.
- Praga 30.03-02.04.2022 (Virtual Conference). ELCC. Battling recurrent SCLC: Emerging therapies for platinum refractory disease.
- 25.04.2023 ESMO GUIDELINES WEBINAR : Treatment sequence in a case of ALK-rearranged NSCLC
- Roma 12.11.2023 XXV AIOM : NSCLC OLTRE LA PRIMA LINEA: QUALI STRATEGIE NEI CASI NON-ONCOGENE ADDICTED METASTATICI O LOCALMENTE AVANZATI
- Roma 8.11.24 XXVI AIOM : NSCLC AVANZATO : TRATTAMENTO DELLA RESISTENZA AD IMMUNOTERAPIA

ABSTRACTS:

- Author of about 400 abstracts/posters presented at national and international meeting

ATTACHEMENTS

ABSTRACT LIST, TRIALS LIST

Il sottoscritto Giuseppe Lo Russo

nato a Catanzaro il 30.10.1982, residente a Milano, in Via Bernardino Bellincione n. 10, c.a.p. 20134, codice fiscale LRSGPP82R30C352F, consapevole delle sanzioni penali previste dall'art. 76 del D.P.R. 28 dicembre 2000, n. 445, per le ipotesi di dichiarazioni mendaci e falsità negli atti ed uso di atti falsi,

DICHIARA

sotto la propria responsabilità, ai sensi degli artt. 46 e 47 del citato decreto, che quanto riportato in questo documento corrisponde a verità

Il sottoscritto esprime altresì il proprio consenso al trattamento dei dati personali, anche di quelli cosiddetti "sensibili" in ordine alla comunicazione ed alla diffusione degli stessi, nell'ambito delle finalità del D.lgs. 30 giugno 2003 n. 196 e s.m.i., nonché del Regolamento UE 2016/679.

Name Lo Russo Giuseppe

Date

Signature